Ngā hua rapu - Lijin Zhao

  • E whakaatu ana i te 1 - 3 hua o te 3
Whakamahine hua
  1. 1
    Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report

    Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report mā Kai Liu, Ziyue Huang, Lijin Zhao, Haitao Zhao

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy

    TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy mā Jin-feng Shen, Zaiyou Dai, Yunsheng Li, Huiping Zhu, Lijin Zhao

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects

    Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects mā Xuan-Yu Gu, Jinlong Huo, Zhiyong Yu, Ji-Chang Jiang, Yaxuan Xu, Lijin Zhao

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: